Alkermes Plc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Good morning, everybody. Thank you for joining us. I'm Terence Flynn, the Biopharma Analyst at Goldman Sachs. We're very pleased to have Alkermes joining us this morning for our virtual conference. From the company, we have Richard Pops, Chairman and CEO; and Sandy Coombs, Vice President of Investor Relations. Thank you both for taking time this morning to be with us. Really appreciate it.
And first, I'm going to turn it over to Rich for some opening remarks before we go into the fireside chat.
Well, good morning, Terence, and good morning, everybody. I won't take long. I'll just say a couple of things that are top of mind for me. One is, at this moment in time, which is this interesting confluence of COVID-19, along with significant civil unrest under -- over about racial disparities in the U.S. It's a moment to remind the world the importance of the biopharmaceutical industry. And in our particular case, in Alkermes case and our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |